FindTrial
Sign In

A prospective, multi-center, randomized controlled clinical trial for perioperative optimal bridge strategy on antithrombotic therapy of patients with a recently implanted coronary drug-eluting stent undergoing non-cardiac surgery

A prospective, multi-center, randomized controlled clinical trial for perioperative optimal bridge strategy on antithrombotic therapy of patients with a recently implanted coronary drug-eluting stent undergoing non-cardiac surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900022351
Enrollment
Unknown
Registered
2019-04-07
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

GP IIb/IIIa group:tirofiban
LWMH group:enoxaparin

Sponsors

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Aged >= 18 year old patients with recently (within previous 6-momth for stable coronary artery disease or within previous 12-month for acute coronary syndromes) drug-eluting stents (DESs) implantation who require dual antiplatelet therapy (DAPT) discontinuation due to undergoing selected middle or high risk of bleeding non-cardiac surgery. All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1. All urgent, and/or low risk of bleeding non-cardiac surgery; 2. PCIs history longer than 6 month for stable coronary artery disease or 12 month for acute coronary syndromes ; 3. ongoing severe bleeding due to other diseases; 4. those with blood Platelet count (PLT) < 60×10^9/L; 5. a stroke within the previous 30 days or a history of haemorrhagic stroke; 6. intracranial disease or bleeding diathesis; 7. contraindicated to use of GPIIb/IIIa receptor blocker or low-molecular-weight heparin; 8. during pregnancy and lactation; 9. those unwilling or unable to sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Blood routine;bleeding and coagulation function;liver function;kidney function;cardiac troponin;urine routine;fecal occult blood test;electrocardiogram;echocardiography;—

Countries

China

Contacts

Public ContactYang Zhenkun

Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine

yangzhenkun2002@hotmail.com+86 13918878748

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026